TipRanks
GR Properties Limited (HK:0108)
:0108
Hong Kong Market
Want to see HK:0108 full AI Analyst Report?

GR Properties Limited (0108) AI Stock Analysis

0 Followers

Top Page

HK:0108

GR Properties Limited

(0108)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - Gpt-5.6Sol)
Rating:46Neutral
Price Target:
HK$2.00
▲(4.71% Upside)
Action:Reiterated
Date:10/31/26
The score is held back primarily by weak and volatile profitability (net losses in four of the last five years and a -33% net margin in 2025) and higher leverage (debt-to-equity ~1.38). Offsetting this, operating and free cash flow improved materially in 2025. Technical signals are mixed but generally soft (price below 20-day and 200-day averages, RSI below 50), and valuation is constrained by a negative P/E with no dividend yield provided.
Positive Factors
Revenue recovery
The return to revenue growth in 2025 indicates that the business regained some top-line momentum after the prior-year decline. If maintained, this provides a broader base for operating leverage and cash generation, although the recent growth record remains uneven.
Negative Factors
Persistent net losses
Repeated net losses and a deeply negative 2025 net margin demonstrate that operating activity has not translated consistently into earnings for shareholders. Continued bottom-line weakness can constrain reinvestment, weaken equity returns, and make profitability improvement a central execution challenge.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue recovery
The return to revenue growth in 2025 indicates that the business regained some top-line momentum after the prior-year decline. If maintained, this provides a broader base for operating leverage and cash generation, although the recent growth record remains uneven.
Read all positive factors

GR Properties Limited (0108) vs. iShares MSCI Hong Kong ETF (EWH)

GR Properties Limited Business Overview & Revenue Model

Company Description
An investment holding company principally engaged in property-related businesses. The company operates through two segments: Property Development and Investment, and Property Management, which provides services for office buildings, residential pr...
How the Company Makes Money
null...

GR Properties Limited Financial Statement Overview

Summary
Cash generation is improving with positive operating cash flow in 2023–2025 and solid 2025 free cash flow (~75M) with strong growth (+63%). However, profitability remains weak and volatile, with net losses in four of the last five years and a sharply negative 2025 net margin (-33%). Balance-sheet risk increased as total debt rose in 2025, lifting debt-to-equity to ~1.38 and reducing financial flexibility.
Income Statement
36
Negative
Balance Sheet
46
Neutral
Cash Flow
58
Neutral
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue404.24M348.91M310.02M352.64M352.28M331.33M
Gross Profit397.35M347.44M220.08M275.88M279.56M250.04M
EBITDA27.19M18.88M-840.68M61.70M-194.62M245.17M
Net Income-182.33M-109.63M-918.50M-129.31M-320.13M207.63M
Balance Sheet
Total Assets6.26B5.74B5.42B6.41B6.24B6.89B
Cash, Cash Equivalents and Short-Term Investments231.06M312.76M311.31M316.82M365.00M304.05M
Total Debt4.04B2.89B1.91B2.70B2.39B2.17B
Total Liabilities5.17B4.80B3.29B3.31B2.99B3.03B
Stockholders Equity1.02B936.36M2.13B3.10B3.25B3.86B
Cash Flow
Free Cash Flow103.04M75.38M79.13M103.25M-179.96M-32.50M
Operating Cash Flow147.57M121.78M80.28M104.22M-179.04M-31.63M
Investing Cash Flow-56.67M-214.24M7.95M-327.49M-136.66M64.19M
Financing Cash Flow34.97M14.28M-199.13M173.70M351.88M-43.75M

GR Properties Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.91
Price Trends
50DMA
2.15
Negative
100DMA
2.00
Positive
200DMA
2.32
Negative
Market Momentum
MACD
0.07
Positive
RSI
42.23
Neutral
STOCH
23.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0108, the sentiment is Negative. The current price of 1.91 is below the 20-day moving average (MA) of 2.48, below the 50-day MA of 2.15, and below the 200-day MA of 2.32, indicating a bearish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 42.23 is Neutral, neither overbought nor oversold. The STOCH value of 23.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0108.

GR Properties Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
HK$10.57B7.3221.17%9.32%10.76%-12.76%
71
Outperform
HK$6.77B9.893.22%5.41%-10.82%-1.24%
68
Neutral
HK$94.67B-46.68-1.12%5.13%-0.55%-337.48%
65
Neutral
$2.17B12.193.79%4.94%3.15%1.96%
63
Neutral
HK$32.21B18.761.21%8.39%9.89%-22.12%
55
Neutral
HK$558.61M-13.70-0.94%7.10%-0.96%91.94%
46
Neutral
HK$7.06B-37.61-18.68%―24.51%80.28%
* Real Estate Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0108
GR Properties Limited
2.13
0.15
7.32%
HK:2669
China Overseas Property Holdings
3.22
-1.35
-29.60%
HK:0101
Hang Lung Properties
6.19
-1.95
-23.98%
HK:0071
Miramar Hotel & Investment Co
9.80
0.54
5.80%
HK:1997
Wharf Real Estate Investment Co
31.18
10.32
49.46%
HK:0225
Pokfulam Development Co. Ltd.
5.07
-0.43
-7.89%

GR Properties Limited Corporate Events

SR Medical Technology Appoints Veteran Engineer Shao Jiyou as Executive Director
Sep 16, 2026
SR Medical Technology Company Limited has appointed Mr. Shao Jiyou as an executive director, effective 16 September 2026. Shao, a professor-level senior engineer with extensive construction and corporate management experience and chairman of BCEG ...
SR Medical Technology Details Board and Committee Structure
Sep 16, 2026
SR Medical Technology Company Limited has outlined the current composition of its board, comprising six executive directors and three independent non-executive directors. The disclosure underscores the mix of management and independent oversight a...
SR Medical Technology Swings to Interim Loss Despite Double‑Digit Revenue Growth
Aug 31, 2026
SR Medical Technology Company Limited reported a strong top‑line performance for the six months ended 30 June 2026, with revenue rising 30.7% year on year to approximately HK$223.1 million. The increase reflects expansion in its medical tech...
SR Medical Technology flags sharp interim loss after cost surge
Aug 26, 2026
SR Medical Technology Company Limited has warned that it expects to post a loss attributable to shareholders of between HK$68 million and HK$73 million for the six months ended 30 June 2026, compared with a profit of about HK$2.1 million a year ea...
SR Medical Technology Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 19, 2026
SR Medical Technology Company Limited has scheduled a board meeting for 31 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider whether to declare, recommend or pay a dividend, a...
SR Medical Technology names seasoned finance executive as new CFO
Aug 13, 2026
SR Medical Technology Company Limited announced that chief financial officer Li Chenji will resign effective 13 August 2026 due to other business commitments, with the board noting there is no disagreement and no issues requiring shareholder atten...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 31, 2026